. Available, has-sante.fr/portail/upload/docs/application/pdf/2009- 02/synthese_inr_1437.pdf 3 ANSM. Bon usage des médicaments antivitamine K (AVK) juillet 2012 Available from, 2014.

E. Etude, Effet Indésirables des Médicaments : Incidence et Risque sur les hospitalisations liées à un effet indésirable médicamenteux, Coordination CRPV de Bordeaux, 2007.

C. Benoit, Enquête sur les conditions de réalisation des prélèvements d'INR à domicile-pile ou face ?, Available fromnumero_etudian t=&numero_resume=318 Site certifié en partenariat avec la Haute Autorité de Santé (HAS), pp.4-9, 2011.

D. Mungall and R. White, Aging and Warfarin Therapy, Annals of Internal Medicine, vol.117, issue.10, pp.878-887, 1992.
DOI : 10.7326/0003-4819-117-10-878

A. Besselaar, Preanalytical variables and off-site blood collection: influences on the results of the prothrombin time/international normalized ratio test and implications for monitoring of oral anticoagulant therapy, Clin Chem, vol.51, issue.3, pp.561-569, 2005.

A. Surdosage-en, situations à risque et accidents hémorragiques Available from : http://www.has-sante

J. Nishiyama, M. Matsuda, G. Urimoto, R. Sakamoto, K. Ito et al., Applicability of a compact PT-INR measuring device CoaguChek XS to perioperative management, Tokai J

A. Lawrie, J. Hills, I. Longair, L. Green, C. Gardiner et al., The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients, Thrombosis Research, vol.130, issue.1, pp.110-114
DOI : 10.1016/j.thromres.2011.08.027

M. Colella, M. Fiusa, F. Orsi, E. De-paula, and J. Annichino-bizzacchi, Performance of a point-of-care device in determining prothrombin time in an anticoagulation clinic, Blood Coagulation & Fibrinolysis, vol.23, issue.2, pp.172-176, 2012.
DOI : 10.1097/MBC.0b013e32835029bf

W. Plesch, T. Wolf, N. Breitenbeck, L. Dikkeschei, A. Cervero et al., Results of the performance verification of the CoaguChek XS system, of the performance verification of the CoaguChek XS system, pp.381-390, 2008.
DOI : 10.1016/j.thromres.2008.04.021

J. Ansell, A. Jacobson, J. Levy, H. Voller, and J. Hasenkam, Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation, International Journal of Cardiology, vol.99, issue.1, pp.37-45, 2005.
DOI : 10.1016/j.ijcard.2003.11.008

C. Heneghan, P. Alonso-coello, J. Garcia-alamino, R. Perera, E. Meats et al., Selfmonitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet, Feb, vol.4367, issue.9508, pp.404-415, 2006.

G. Helft, J. Blacher, G. Labarere, J. Yver, J. Satger et al., Automesure de l'INR : pour quels patientsAVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study, Presse Med. J Gen Intern Med, vol.3723, issue.9, pp.1441-1447, 2008.

. Guide-méthodologique, Structuration d'un programme d'éducation thérapeutique du patient dans le champ des maladies chroniques Avalaible from, 2007.

Y. Benhamou, L. Cam-duchez, V. Schneller, J. Cailleux, N. Magne et al., Exp??rience d???un centre de suivi et de conseil des traitements anticoagulants oraux en m??decine de ville??: r??sultats ?? cinq ans, La Revue de M??decine Interne, vol.30, issue.7, pp.567-72, 2009.
DOI : 10.1016/j.revmed.2009.02.004

P. Léger, C. J. Baneu, B. Boccalon, and H. , Les cliniques d'anticoagulants, Sang Thrombose Vaisseaux, vol.15, issue.6, pp.288-90, 2003.

H. Boccalon, A. Bura-rivière, J. Cambus, P. Mismetti, and S. Laporte, Comparaison de??deux??m??thodes de??gestion d'un traitement antivitamine K: clinique des??anticoagulants (CAC) versus suivi conventionnel: ??tude randomis??e de??1005 patients, Journal des Maladies Vasculaires, vol.32, p.59, 2007.
DOI : 10.1016/j.jmv.2007.06.049

L. Gilles, T. Pape-christensen, C. Jensen, T. Larsen, M. Maegaard et al., AnaStats Tours Available from : www.anastats.fr/stats/Documents/Conferences/Petits%20echantillons

D. Adcock, D. Kressin, and R. Marlar, The effect of time and temperature variables on routine coagulation tests, Blood Coagulation & Fibrinolysis, vol.9, issue.6, pp.463-70, 1998.
DOI : 10.1097/00001721-199809000-00002

K. Azarnoush, E. Dorigo, B. Pereira, C. Dauphin, E. Geoffroy et al., Mid-term results of self-testing of the international normalized ratio in adults with a mechanical heart valve, Thrombosis Research, vol.133, issue.2, pp.149-53, 2014.
DOI : 10.1016/j.thromres.2013.09.013

H. Bon-usage-du-médicament, Fibrillation auriculaire non valvulaire Quelle place pour les anticoagulants oraux non antivitamine K : apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®). septembre 2013 Available from

L. Wallentin, S. Yusuf, M. Ezekowitz, M. Alings, M. Flather et al., Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, The Lancet, vol.376, issue.9745, pp.975-83, 2010.
DOI : 10.1016/S0140-6736(10)61194-4

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111